English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/124262
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue

AuthorsVizcaíno, Carolina ; Núñez, Luz-Elena; Morís, Francisco; Portugal, José
Issue Date11-Aug-2014
PublisherPublic Library of Science
CitationPLoS ONE 9(8): e104687 (2014)
AbstractOvarian cancer has a poor prognosis due to intrinsic or acquired resistance to some cytotoxic drugs, raising the interest in new DNA-binding agents such as mithramycin analogues as potential chemotherapeutic agents in gynecological cancer. Using a genome-wide approach, we have analyzed gene expression in A2780 human ovarian carcinoma cells treated with the novel mithramycin analogue DIG-MSK (demycarosyl-3D-β-D-digitoxosyl-mithramycin SK) that binds to C+G-rich DNA sequences. Nanomolar concentrations of DIG-MSK abrogated the expression of genes involved in a variety of cell processes including transcription regulation and tumor development, which resulted in cell death. Some of those genes have been associated with cell proliferation and poor prognosis in ovarian cancer. Sp1 transcription factor regulated most of the genes that were down-regulated by the drug, as well as the up-regulation of other genes mainly involved in response to cell stress. The effect of DIG-MSK in the control of gene expression by other transcription factors was also explored. Some of them, such as CREB, E2F and EGR1, also recognize C/G-rich regions in gene promoters, which encompass potential DIG-MSK binding sites. DIG-MSK affected several biological processes and molecular functions related to transcription and its cellular regulation in A2780 cells, including transcription factor activity. This new compound might be a promising drug for the treatment of ovarian cancer. © 2014 Vizcaíno et al.
Publisher version (URL)http://dx.doi.org/10.1371/journal.pone.0104687
URIhttp://hdl.handle.net/10261/124262
DOIhttp://dx.doi.org/10.1371/journal.pone.0104687
Identifiersdoi: 10.1371/journal.pone.0104687
issn: 1932-6203
Appears in Collections:(IBMB) Artículos
Files in This Item:
File Description SizeFormat 
Vizcaino-PLoS-ONE-2014-v9-e0104687.pdf1,04 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.